Registration Options

Activity Date: 04/18/2023

AAPP 2023 registration is closed.

Session Time and Location

The live session is complete.

Session Summary

Prior to the presentation, lunch will be served from 11:15-11:30 AM Eastern. The program should begin right at 11:30 AM Eastern; however, small delays are possible due to the meal. We thank you in advance for your patience.

Currently approved drugs for schizophrenia have proven useful; however, unmet medical needs still exist for this patient population. This program will shed light on an evolving class of investigational therapeutics that have shown great promise in schizophrenia by targeting muscarinic acetylcholine receptors in the brain.

Faculty Information and Disclosures

Learning Objectives

  1. Illustrate the evolving understanding of the psychopharmacology of schizophrenia with respect to muscarinic receptor–based mechanisms of action
  2. Introduce muscarinic receptor–modulating therapeutics currently under investigation for use in schizophrenia with a focus on muscarinic agonists
  3. Demonstrate how modulating muscarinic receptor activity may play a role in treating schizophrenia

Continuing Education Credit and Disclosures

View AAPP's Privacy Policy

AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.

Questions? Contact AAPP.

Grant Support

Supported by